This treatment strategy of PD-1 inhibitor ICB for early-stage cancer patients was successfully incorporated in non-small cell lung cancer (NSCLC) (42), and our study warranted the potential of this strategy for early-stage GC patients. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.